Insider Selling: Emergent Biosolutions, Inc. (EBS) CEO Sells 20,000 Shares of Stock

Emergent Biosolutions, Inc. (NYSE:EBS) CEO Daniel Abdun-Nabi sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $45.99, for a total transaction of $919,800.00. Following the completion of the transaction, the chief executive officer now owns 224,134 shares of the company’s stock, valued at $10,307,922.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Daniel Abdun-Nabi also recently made the following trade(s):

  • On Friday, November 3rd, Daniel Abdun-Nabi sold 31,508 shares of Emergent Biosolutions stock. The stock was sold at an average price of $42.77, for a total transaction of $1,347,597.16.
  • On Wednesday, September 27th, Daniel Abdun-Nabi sold 15,000 shares of Emergent Biosolutions stock. The stock was sold at an average price of $39.92, for a total transaction of $598,800.00.

Emergent Biosolutions, Inc. (NYSE:EBS) traded up $0.60 during trading hours on Thursday, hitting $46.08. 324,100 shares of the stock were exchanged, compared to its average volume of 345,440. Emergent Biosolutions, Inc. has a 12 month low of $27.94 and a 12 month high of $46.34. The company has a market capitalization of $1,882.66, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 1.26 and a beta of 1.24. The company has a debt-to-equity ratio of 0.38, a quick ratio of 6.46 and a current ratio of 7.37.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a net margin of 15.60% and a return on equity of 15.20%. The company had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. During the same quarter last year, the firm posted $0.56 earnings per share. The company’s quarterly revenue was up 4.6% compared to the same quarter last year. research analysts expect that Emergent Biosolutions, Inc. will post 1.64 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in EBS. Riverhead Capital Management LLC increased its position in Emergent Biosolutions by 102.8% during the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 1,542 shares during the period. Ameritas Investment Partners Inc. boosted its stake in Emergent Biosolutions by 23.2% during the second quarter. Ameritas Investment Partners Inc. now owns 3,118 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 587 shares in the last quarter. First Quadrant L P CA acquired a new stake in Emergent Biosolutions during the third quarter worth $157,000. Meeder Asset Management Inc. boosted its stake in Emergent Biosolutions by 94.7% during the third quarter. Meeder Asset Management Inc. now owns 4,732 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 2,302 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in Emergent Biosolutions during the third quarter worth $191,000. 92.70% of the stock is currently owned by institutional investors and hedge funds.

EBS has been the subject of several research reports. Zacks Investment Research upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Wednesday, October 25th. Wells Fargo & Company restated an “outperform” rating and set a $43.00 price target (up from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Finally, BidaskClub raised shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Friday, August 25th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Emergent Biosolutions currently has a consensus rating of “Buy” and an average price target of $46.00.

WARNING: “Insider Selling: Emergent Biosolutions, Inc. (EBS) CEO Sells 20,000 Shares of Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/12/14/insider-selling-emergent-biosolutions-inc-ebs-ceo-sells-20000-shares-of-stock.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply